Active substance
Danazol
- SFDA 4
- US FDA 5
- Health Canada 2
- US price lines 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DANOL CAPS 100MG | 100 mg | Capsule · Oral use | 60 Blister | SAR 108.65 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
| DANOL CAPS 100MG | 100 mg | Capsule · Oral use | 60 Blister | SAR 108.65 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
| DANOL CAPS 200MG | 200 mg | Capsule · Oral use | 60 Blister | SAR 206.20 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
| DANOL CAPS 200MG | 200 mg | Capsule · Oral use | 60 Blister | SAR 206.20 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DANAZOL | 200MG; 100MG; 50MG | capsule · oral | BARR | Prescription | 9 Aug 1996 |
| DANAZOL | 200MG; 50MG; 100MG | capsule · oral | LANNETT CO INC | Prescription | 28 Sep 2005 |
| DANAZOL | 50MG; 100MG | capsule · oral | LANNETT | Prescription | 19 Apr 2007 |
| DANOCRINE | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | SANOFI AVENTIS US | Discontinued | 21 Jun 1976 |
| DANAZOL | 200MG | capsule · oral | AM THERAP | Discontinued |
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DANAZOL 100 MG CAPSULE | $2.23171 | per EA | 23 Sep 2026 |
| US NADAC | DANAZOL 200 MG CAPSULE | $2.65221 | per EA | 23 Sep 2026 |
| US NADAC | DANAZOL 50 MG CAPSULE | $1.56444 | per EA | 22 Apr 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.